The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|8|3|327-337

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.8, Iss.3, 2010-05, pp. : 327-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Type 2 Diabetes Mellitus and Cardiovascular Exercise Performance

By Regensteiner Judith G.  

Reviews in Endocrine and Metabolic Disorders, Vol. 5, Iss. 3, 2004-08 ,pp. : 269-276

Springer Publishing Company

Access to resources Recommend Favorite

Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications

By Rachmani R.   Slavachevski I.   Levi Z.   Zadok B.-S.   Kedar Y.   Ravid M.  

European Journal of Internal Medicine, Vol. 13, Iss. 7, 2002-10 ,pp. : 428-433

Elsevier

Access to resources Recommend Favorite

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes - Influence of prior antidiabetic drug regimen

By Rendell M.S.   Glazer N.B.   Ye Z.  

Journal of Diabetes and its Complications, Vol. 17, Iss. 4, 2003-07 ,pp. : 211-217

Elsevier

Access to resources Recommend Favorite

Metformin Beyond Diabetes: New Life for an Old Drug

By  

Current Diabetes Reviews, Vol. 2, Iss. 3, 2006-08 ,pp. : 307-315

Bentham Science Publishers

Access to resources Recommend Favorite

Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug

By  

Current Diabetes Reviews, Vol. 9, Iss. 6, 2013-11 ,pp. : 478-490

Bentham Science Publishers

Access to resources Recommend Favorite